Scarica l'app Stockscreener
935.58
1.98%
-18.94
Dopo l'orario di chiusura:
935.98
0.40
+0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod - Genetic Engineering and Biotechnology News
Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly's New TreatmentsNews and Statistics - IndexBox
AI Models Split on Eli Lilly (LLY) as Growth Strength Meets Premium Valuation - TipRanks
Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster” - Insider Monkey
Eli Lilly (LLY) Is Up 6.5% After FDA Clears Anytime Oral GLP-1 Foundayo for Obesity Treatment - simplywall.st
Jim Cramer Likes Eli Lilly’s (LLY) New Deal - Insider Monkey
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight - The Motley Fool
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight - The Motley Fool
Eli Lilly and Company $LLY Shares Sold by Weatherly Asset Management L. P. - MarketBeat
Frank Rimerman Advisors Boosts Eli Lilly Stock Position - National Today
Mounjaro: Eli Lilly's GLP-1 Powerhouse Driving Weight Loss Revolution and Investor Interest in North - AD HOC NEWS
Eli Lilly and Company $LLY is Tema Etfs LLC's 4th Largest Position - MarketBeat
Elser Financial Planning Boosts Stake in Eli Lilly - National Today
Elser Financial Planning Inc Has $28.18 Million Stake in Eli Lilly and Company $LLY - MarketBeat
How Eli Lilly’s oral GLP-1 could change the obesity drug market - Healthcare Brew
Eli Lilly (LLY) Valuation Check As Foundayo Oral GLP 1 Approval Lifts Obesity Growth Story - simplywall.st
Eli Lilly’s new GLP-1 weight loss pill Foundayo receives FDA approval - InkFreeNews.com
Eli Lilly (LLY) Receives FDA Approval for Foundayo Weight Management Pill - Insider Monkey
Eli Lilly’s LY4060874 Phase 1 Readout: What a Quiet Pipeline Update Means for LLY Investors - TipRanks
Eli Lilly and Company stock: Foundayo approval ignites 2026 boom? - AD HOC NEWS
To celebrate its anniversary, Eli Lilly marks 150 years of everything else - PRWeek
Should You Be Adding Eli Lilly (NYSE:LLY) To Your Watchlist Today? - 富途牛牛
Novo Nordisk Weight Loss Pill Outperforms Eli Lilly Rival in New Clinical Trial Data - TIKR.com
Nisa Investment Advisors Boosts Stake in Eli Lilly - National Today
Nisa Investment Advisors LLC Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Moody Lynn & Lieberson LLC Purchases 2,657 Shares of Eli Lilly and Company $LLY - MarketBeat
Nikulski Financial Inc. Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (LLY) expands Zepbound access as pricing reforms boost long-term growth outlook - MSN
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions - Manufacturing Chemist
Eli Lilly Stock (LLY) Opinions on FDA Approval of Foundayo - Moomoo
Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion - thelec.net
FDA approves Eli Lilly's new weight loss pill with no food restrictions - qz.com
Eli Lilly's Foundayo Pill Approved: Stock Gains, Launch April 6, 2026News and Statistics - IndexBox
Eli Lilly, Novo Nordisk Intensify Competition With Oral Obesity Drugs - thelec.net
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why - Yahoo Finance Singapore
Eli Lilly and Company (NYSE:LLY) Shares Down 2%Should You Sell? - MarketBeat
Novo Nordisk: Competing In A Duopoly (TSX:NOVO:CA) - Seeking Alpha
A new weight-loss pill is here, and it could reshape the GLP-1 market - Fast Company
Stocks with rising composite ratings: Eli Lilly - MSN
LLY Stock Quote Price and Forecast - CNN
Stock Quote & Chart | Eli Lilly and Company - investor.lilly.com
Explainer: What to Know About Foundayo, Eli Lilly’s New Once-Daily Weight-Loss Pill - U.S. News & World Report
Doctor shares what to know about new weight-loss pill Foundayo - ABC News
Eli Lilly Stock Surges 3.6% on Strong Trading - National Today
What you need to know about Eli Lilly’s Foundayo weight loss pill - Houston Chronicle
FDA Approves New GLP-1 Weight Loss Pill from Eli Lilly - People.com
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring - FinancialContent
Eli Lilly’s Foundayo Pill Resets Obesity Portfolio And Valuation Debate - simplywall.st
The weight-loss drug rivalry heats up as another GLP-1 pill gains FDA approval - Scientific American
Eli Lilly launches Zepbound KwikPen on Ro (LLY:NYSE) - Seeking Alpha
Eli Lilly (LLY) Partners with Ro to Launch Zepbound KwikPen Nati - GuruFocus
Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating - drugdiscoverytrends.com
Ro says working with Eli Lilly to launch Zepbound Kwikpen nationwide on its platform - MarketScreener
RO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND® - PR Newswire
Bank of America sees Eli Lilly’s Foundayo as preferred oral GLP-1 - Yahoo Finance
Eli Lilly (NYSE:LLY) Tracks Clinical Pipeline Growth In S&P 500 Fund - Kalkine Media
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience - MarketBeat
Lilly's obesity pill Foundayo gains early blockbuster forecast as analysts float 5M+ prescriptions in 2026 - Fierce Pharma
Eli Lilly (LLY) to Acquire Centessa Pharmaceuticals in $7.8B Deal - Insider Monkey
0.44%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):